TW201242976A - Anti-IL-12/IL-23 antibodies and uses thereof - Google Patents

Info

Publication number

TW201242976A

TW201242976A TW101100711A TW101100711A TW201242976A TW 201242976 A TW201242976 A TW 201242976A TW 101100711 A TW101100711 A TW 101100711A TW 101100711 A TW101100711 A TW 101100711A TW 201242976 A TW201242976 A TW 201242976A

Authority

TW

Taiwan

Prior art keywords

amino acid

acid residue

antibody

seq

residues

Prior art date

2011-01-07

Links

• Espacenet
• Global Dossier
• Discuss

• 102000013264 Interleukin-23 Human genes 0.000 title claims abstract description 228
• 108010065637 Interleukin-23 Proteins 0.000 title claims abstract description 228
• 125000000539 amino acid group Chemical group 0.000 claims abstract description 839
• 230000027455 binding Effects 0.000 claims abstract description 462
• 239000000427 antigen Substances 0.000 claims abstract description 305
• 108091007433 antigens Proteins 0.000 claims abstract description 303
• 102000036639 antigens Human genes 0.000 claims abstract description 303
• 238000000034 method Methods 0.000 claims abstract description 143
• 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 64
• 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 64
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 42
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 42
• 239000013598 vector Substances 0.000 claims abstract description 29
• 239000000203 mixture Substances 0.000 claims abstract description 21
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 140
• 150000001413 amino acids Chemical class 0.000 claims description 103
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 96
• 230000000694 effects Effects 0.000 claims description 87
• 239000002253 acid Substances 0.000 claims description 34
• 238000006467 substitution reaction Methods 0.000 claims description 31
• 230000014509 gene expression Effects 0.000 claims description 24
• 150000001412 amines Chemical class 0.000 claims description 23
• 125000003118 aryl group Chemical group 0.000 claims description 17
• 239000000523 sample Substances 0.000 claims description 16
• 230000001225 therapeutic effect Effects 0.000 claims description 16
• 230000004071 biological effect Effects 0.000 claims description 14
• 230000001105 regulatory effect Effects 0.000 claims description 13
• 230000002401 inhibitory effect Effects 0.000 claims description 10
• 125000003277 amino group Chemical group 0.000 claims description 8
• 230000007423 decrease Effects 0.000 claims description 8
• 239000008194 pharmaceutical composition Substances 0.000 claims description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
• 239000003795 chemical substances by application Substances 0.000 claims description 7
• 230000002103 transcriptional effect Effects 0.000 claims description 4
• 239000012472 biological sample Substances 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 239000012867 bioactive agent Substances 0.000 claims description 2
• 239000002689 soil Substances 0.000 claims description 2
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
• 241000239226 Scorpiones Species 0.000 claims 1
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
• 125000001424 substituent group Chemical group 0.000 claims 1
• 241000282414 Homo sapiens Species 0.000 description 213
• 229940124829 interleukin-23 Drugs 0.000 description 203
• 210000004027 cell Anatomy 0.000 description 138
• 108090000623 proteins and genes Proteins 0.000 description 134
• 235000001014 amino acid Nutrition 0.000 description 110
• 229940024606 amino acid Drugs 0.000 description 100
• 102000004169 proteins and genes Human genes 0.000 description 97
• 235000018102 proteins Nutrition 0.000 description 95
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 74
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 73
• 239000013078 crystal Substances 0.000 description 70
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 60
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 58
• 230000035772 mutation Effects 0.000 description 53
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 42
• 108090000765 processed proteins & peptides Proteins 0.000 description 42
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 37
• 239000012634 fragment Substances 0.000 description 30
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
• 230000004927 fusion Effects 0.000 description 28
• 102000004127 Cytokines Human genes 0.000 description 27
• 108090000695 Cytokines Proteins 0.000 description 27
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 27
• 241000700159 Rattus Species 0.000 description 27
• 201000010099 disease Diseases 0.000 description 27
• 238000006206 glycosylation reaction Methods 0.000 description 27
• 230000013595 glycosylation Effects 0.000 description 26
• 241000699666 Mus <mouse, genus> Species 0.000 description 25
• 230000003993 interaction Effects 0.000 description 25
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 24
• 108060003951 Immunoglobulin Proteins 0.000 description 24
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 24
• 206010028980 Neoplasm Diseases 0.000 description 24
• 102000018358 immunoglobulin Human genes 0.000 description 24
• 108020004414 DNA Proteins 0.000 description 23
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 23
• 108091023037 Aptamer Proteins 0.000 description 22
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 22
• 241001529936 Murinae Species 0.000 description 22
• 238000004519 manufacturing process Methods 0.000 description 22
• 102000004196 processed proteins & peptides Human genes 0.000 description 22
• 239000002585 base Substances 0.000 description 21
• 230000000890 antigenic effect Effects 0.000 description 20
• 238000004458 analytical method Methods 0.000 description 19
• 239000013604 expression vector Substances 0.000 description 19
• 210000004602 germ cell Anatomy 0.000 description 19
• 238000003556 assay Methods 0.000 description 18
• 229920001184 polypeptide Polymers 0.000 description 18
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 17
• 239000003814 drug Substances 0.000 description 17
• 229910052739 hydrogen Inorganic materials 0.000 description 16
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
• 125000004429 atom Chemical group 0.000 description 15
• -1 cyclic oxime Chemical class 0.000 description 15
• 239000001257 hydrogen Substances 0.000 description 15
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 14
• 241000699670 Mus sp. Species 0.000 description 14
• 230000002950 deficient Effects 0.000 description 14
• 206010039073 rheumatoid arthritis Diseases 0.000 description 14
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 13
• 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 13
• 150000001875 compounds Chemical class 0.000 description 13
• 238000000338 in vitro Methods 0.000 description 13
• 238000001727 in vivo Methods 0.000 description 13
• 201000006417 multiple sclerosis Diseases 0.000 description 13
• 102000005962 receptors Human genes 0.000 description 13
• 108020003175 receptors Proteins 0.000 description 13
• 208000011231 Crohn disease Diseases 0.000 description 12
• 210000000130 stem cell Anatomy 0.000 description 12
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 12
• 238000005516 engineering process Methods 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000001976 improved effect Effects 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 238000003259 recombinant expression Methods 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 208000023275 Autoimmune disease Diseases 0.000 description 10
• 208000019693 Lung disease Diseases 0.000 description 10
• 239000002202 Polyethylene glycol Substances 0.000 description 10
• 206010036790 Productive cough Diseases 0.000 description 10
• 229920001223 polyethylene glycol Polymers 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 208000024794 sputum Diseases 0.000 description 10
• 210000003802 sputum Anatomy 0.000 description 10
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 9
• 108010047620 Phytohemagglutinins Proteins 0.000 description 9
• 210000001744 T-lymphocyte Anatomy 0.000 description 9
• 230000001363 autoimmune Effects 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 230000001885 phytohemagglutinin Effects 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 102000014914 Carrier Proteins Human genes 0.000 description 8
• 102100037362 Fibronectin Human genes 0.000 description 8
• 108010067306 Fibronectins Proteins 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
• 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 206010057190 Respiratory tract infections Diseases 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 230000001010 compromised effect Effects 0.000 description 8
• 238000002425 crystallisation Methods 0.000 description 8
• 230000008025 crystallization Effects 0.000 description 8
• 210000000987 immune system Anatomy 0.000 description 8
• 239000011159 matrix material Substances 0.000 description 8
• 231100000350 mutagenesis Toxicity 0.000 description 8
• 239000002773 nucleotide Substances 0.000 description 8
• 125000003729 nucleotide group Chemical group 0.000 description 8
• 239000004471 Glycine Substances 0.000 description 7
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 7
• 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 7
• 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 7
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 7
• 201000004681 Psoriasis Diseases 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 230000005847 immunogenicity Effects 0.000 description 7
• 229940117681 interleukin-12 Drugs 0.000 description 7
• 125000005647 linker group Chemical group 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 210000002706 plastid Anatomy 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 230000028327 secretion Effects 0.000 description 7
• 238000012876 topography Methods 0.000 description 7
• 230000009261 transgenic effect Effects 0.000 description 7
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
• 102220468836 Albumin_D87N_mutation Human genes 0.000 description 6
• 238000002965 ELISA Methods 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 208000029523 Interstitial Lung disease Diseases 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• 108010076504 Protein Sorting Signals Proteins 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 238000013461 design Methods 0.000 description 6
• 239000012636 effector Substances 0.000 description 6
• 229940088598 enzyme Drugs 0.000 description 6
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 6
• 229940088597 hormone Drugs 0.000 description 6
• 239000005556 hormone Substances 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 230000001771 impaired effect Effects 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 239000004615 ingredient Substances 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 201000000050 myeloid neoplasm Diseases 0.000 description 6
• 150000002923 oximes Chemical class 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 230000035755 proliferation Effects 0.000 description 6
• 230000000717 retained effect Effects 0.000 description 6
• 241000894007 species Species 0.000 description 6
• 238000010561 standard procedure Methods 0.000 description 6
• 206010005089 Blast cell proliferation Diseases 0.000 description 5
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 5
• 108090001090 Lectins Proteins 0.000 description 5
• 102000004856 Lectins Human genes 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 102000005886 STAT4 Transcription Factor Human genes 0.000 description 5
• 108010019992 STAT4 Transcription Factor Proteins 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 230000002776 aggregation Effects 0.000 description 5
• 238000004220 aggregation Methods 0.000 description 5
• 230000001580 bacterial effect Effects 0.000 description 5
• 108091008324 binding proteins Proteins 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 150000001720 carbohydrates Chemical class 0.000 description 5
• 235000018417 cysteine Nutrition 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
• 238000010494 dissociation reaction Methods 0.000 description 5
• 230000005593 dissociations Effects 0.000 description 5
• 235000013601 eggs Nutrition 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 238000002649 immunization Methods 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 239000002523 lectin Substances 0.000 description 5
• 210000002540 macrophage Anatomy 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 230000003278 mimic effect Effects 0.000 description 5
• 230000003472 neutralizing effect Effects 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 108010078791 Carrier Proteins Proteins 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• 108010074328 Interferon-gamma Proteins 0.000 description 4
• 102000008070 Interferon-gamma Human genes 0.000 description 4
• 208000012659 Joint disease Diseases 0.000 description 4
• 108050006654 Lipocalin Proteins 0.000 description 4
• 102000019298 Lipocalin Human genes 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 206010037575 Pustular psoriasis Diseases 0.000 description 4
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
• 108700019146 Transgenes Proteins 0.000 description 4
• 206010052779 Transplant rejections Diseases 0.000 description 4
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 210000003969 blast cell Anatomy 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 239000013256 coordination polymer Substances 0.000 description 4
• 238000002447 crystallographic data Methods 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 210000004443 dendritic cell Anatomy 0.000 description 4
• 239000000539 dimer Substances 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000002209 hydrophobic effect Effects 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 229960003130 interferon gamma Drugs 0.000 description 4
• 230000014828 interferon-gamma production Effects 0.000 description 4
• 238000006317 isomerization reaction Methods 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 206010025135 lupus erythematosus Diseases 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 230000006320 pegylation Effects 0.000 description 4
• 238000002823 phage display Methods 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 238000010187 selection method Methods 0.000 description 4
• 238000002741 site-directed mutagenesis Methods 0.000 description 4
• 210000004989 spleen cell Anatomy 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 238000002424 x-ray crystallography Methods 0.000 description 4
• 206010069754 Acquired gene mutation Diseases 0.000 description 3
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 102000002090 Fibronectin type III Human genes 0.000 description 3
• 108050009401 Fibronectin type III Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 108010017515 Interleukin-12 Receptors Proteins 0.000 description 3
• 102000004560 Interleukin-12 Receptors Human genes 0.000 description 3
• 102100036672 Interleukin-23 receptor Human genes 0.000 description 3
• 208000016604 Lyme disease Diseases 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
• 108010006232 Neuraminidase Proteins 0.000 description 3
• 102000005348 Neuraminidase Human genes 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 201000009594 Systemic Scleroderma Diseases 0.000 description 3
• 206010042953 Systemic sclerosis Diseases 0.000 description 3
• 210000004241 Th2 cell Anatomy 0.000 description 3
• 108010022394 Threonine synthase Proteins 0.000 description 3
• 206010047115 Vasculitis Diseases 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 230000009830 antibody antigen interaction Effects 0.000 description 3
• 238000011091 antibody purification Methods 0.000 description 3
• 150000004982 aromatic amines Chemical class 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 150000007942 carboxylates Chemical class 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 238000003776 cleavage reaction Methods 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 102000004419 dihydrofolate reductase Human genes 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 108020001507 fusion proteins Proteins 0.000 description 3
• 102000037865 fusion proteins Human genes 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 229940022353 herceptin Drugs 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 238000000099 in vitro assay Methods 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 229920005610 lignin Polymers 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 239000007937 lozenge Substances 0.000 description 3
• 230000014759 maintenance of location Effects 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000000159 protein binding assay Methods 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 230000008707 rearrangement Effects 0.000 description 3
• 102200081899 rs137854507 Human genes 0.000 description 3
• 230000007017 scission Effects 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 230000037439 somatic mutation Effects 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 125000000647 trehalose group Chemical group 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
• JINGUCXQUOKWKH-UHFFFAOYSA-N 2-aminodecanoic acid Chemical group CCCCCCCCC(N)C(O)=O JINGUCXQUOKWKH-UHFFFAOYSA-N 0.000 description 2
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• 108010032595 Antibody Binding Sites Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 108010029697 CD40 Ligand Proteins 0.000 description 2
• 102100032937 CD40 ligand Human genes 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 108010040721 Flagellin Proteins 0.000 description 2
• 108010060309 Glucuronidase Proteins 0.000 description 2
• 102000053187 Glucuronidase Human genes 0.000 description 2
• 108010068370 Glutens Proteins 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
• 238000012450 HuMAb Mouse Methods 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 206010022489 Insulin Resistance Diseases 0.000 description 2
• 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
• 101710187487 Interleukin-12 subunit beta Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 102000000588 Interleukin-2 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 201000011152 Pemphigus Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• 206010057244 Post viral fatigue syndrome Diseases 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 102220481026 Protein FAM151A_N87D_mutation Human genes 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• 108020004682 Single-Stranded DNA Proteins 0.000 description 2
• 208000006045 Spondylarthropathies Diseases 0.000 description 2
• 108010088160 Staphylococcal Protein A Proteins 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 102000002933 Thioredoxin Human genes 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000004357 Transferases Human genes 0.000 description 2
• 108090000992 Transferases Proteins 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 240000006365 Vitis vinifera Species 0.000 description 2
• 235000014787 Vitis vinifera Nutrition 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000008033 biological extinction Effects 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 238000005251 capillar electrophoresis Methods 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000009137 competitive binding Effects 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 238000010276 construction Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 239000002577 cryoprotective agent Substances 0.000 description 2
• 102000003675 cytokine receptors Human genes 0.000 description 2
• 108010057085 cytokine receptors Proteins 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 230000003176 fibrotic effect Effects 0.000 description 2
• 101150023212 fut8 gene Proteins 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 235000021312 gluten Nutrition 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 239000000185 hemagglutinin Substances 0.000 description 2
• 229960001340 histamine Drugs 0.000 description 2
• 229940040731 human interleukin-12 Drugs 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• 238000003364 immunohistochemistry Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000005462 in vivo assay Methods 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 229940102223 injectable solution Drugs 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 230000002452 interceptive effect Effects 0.000 description 2
• 238000001155 isoelectric focusing Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229960004452 methionine Drugs 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 238000001823 molecular biology technique Methods 0.000 description 2
• 230000004001 molecular interaction Effects 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 150000002772 monosaccharides Chemical class 0.000 description 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• 238000011533 pre-incubation Methods 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 210000001236 prokaryotic cell Anatomy 0.000 description 2
• 108020001580 protein domains Proteins 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 230000004850 protein–protein interaction Effects 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 238000001525 receptor binding assay Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 229940116176 remicade Drugs 0.000 description 2
• 238000009877 rendering Methods 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 102200102602 rs62635018 Human genes 0.000 description 2
• 102220051012 rs727503514 Human genes 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 230000001568 sexual effect Effects 0.000 description 2
• 230000009450 sialylation Effects 0.000 description 2
• 229940126586 small molecule drug Drugs 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 210000001179 synovial fluid Anatomy 0.000 description 2
• 230000009897 systematic effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 108060008226 thioredoxin Proteins 0.000 description 2
• 229940094937 thioredoxin Drugs 0.000 description 2
• 230000006016 thyroid dysfunction Effects 0.000 description 2
• 238000003325 tomography Methods 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 210000005253 yeast cell Anatomy 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
• QEIFSLUFHRCVQL-UHFFFAOYSA-N (5-bromo-4-chloro-1h-indol-3-yl) hydrogen phosphate;(4-methylphenyl)azanium Chemical compound CC1=CC=C(N)C=C1.C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QEIFSLUFHRCVQL-UHFFFAOYSA-N 0.000 description 1
• HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
• BOKGTLAJQHTOKE-UHFFFAOYSA-N 1,5-dihydroxynaphthalene Chemical compound C1=CC=C2C(O)=CC=CC2=C1O BOKGTLAJQHTOKE-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• XCSYDKNASASYDE-UHFFFAOYSA-N 2-aminoethanol hydrazine Chemical compound C(O)CN.NN XCSYDKNASASYDE-UHFFFAOYSA-N 0.000 description 1
• YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
• UJKDYMOBUGTJLZ-UHFFFAOYSA-N 2-azanylpentanedioic acid Chemical compound OC(=O)C(N)CCC(O)=O.OC(=O)C(N)CCC(O)=O UJKDYMOBUGTJLZ-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
• 241000242759 Actiniaria Species 0.000 description 1
• 101710186708 Agglutinin Proteins 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 102000008102 Ankyrins Human genes 0.000 description 1
• 241000239290 Araneae Species 0.000 description 1
• 241001440311 Armada Species 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 206010003267 Arthritis reactive Diseases 0.000 description 1
• 241000186063 Arthrobacter Species 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 1
• 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 241001674044 Blattodea Species 0.000 description 1
• 241001474374 Blennius Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 206010055113 Breast cancer metastatic Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 206010006448 Bronchiolitis Diseases 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 1
• 101100394073 Caenorhabditis elegans hil-1 gene Proteins 0.000 description 1
• 101100177114 Caenorhabditis elegans his-69 gene Proteins 0.000 description 1
• 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
• 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 235000016795 Cola Nutrition 0.000 description 1
• 244000228088 Cola acuminata Species 0.000 description 1
• 235000011824 Cola pachycarpa Nutrition 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102100024203 Collagen alpha-1(XIV) chain Human genes 0.000 description 1
• 101710106877 Collagen alpha-1(XIV) chain Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
• 108010002947 Connectin Proteins 0.000 description 1
• 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000195493 Cryptophyta Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
• 102100036509 Erythropoietin receptor Human genes 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000007984 Female Infertility Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
• 101150074355 GS gene Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 241000237858 Gastropoda Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229940122069 Glycosidase inhibitor Drugs 0.000 description 1
• 108700023372 Glycosyltransferases Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• 102100020948 Growth hormone receptor Human genes 0.000 description 1
• 241000989913 Gunnera petaloidea Species 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000031856 Haemosiderosis Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 description 1
• 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
• 101001090483 Homo sapiens Glutathione S-transferase LANCL1 Proteins 0.000 description 1
• 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
• 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 1
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
• 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 1
• 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
• 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
• 101710146024 Horcolin Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 208000000038 Hypoparathyroidism Diseases 0.000 description 1
• 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010021531 Impetigo Diseases 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 206010021928 Infertility female Diseases 0.000 description 1
• 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
• 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 101710195550 Interleukin-23 receptor Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 101710189395 Lectin Proteins 0.000 description 1
• 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
• 208000012309 Linear IgA disease Diseases 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 208000007466 Male Infertility Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 101710179758 Mannose-specific lectin Proteins 0.000 description 1
• 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
• 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
• 108091092878 Microsatellite Proteins 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101000763311 Mus musculus Thrombomodulin Proteins 0.000 description 1
• 241000238367 Mya arenaria Species 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
• 108050000637 N-cadherin Proteins 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 101710089162 Neuroglian Proteins 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 102220627452 Paired immunoglobulin-like type 2 receptor alpha_L95A_mutation Human genes 0.000 description 1
• 241000282320 Panthera leo Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
• 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
• 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 101001090485 Rattus norvegicus Glutathione S-transferase LANCL1 Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
• 102000001712 STAT5 Transcription Factor Human genes 0.000 description 1
• 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 239000002262 Schiff base Substances 0.000 description 1
• 150000004753 Schiff bases Chemical class 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 241000270295 Serpentes Species 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 108010068542 Somatotropin Receptors Proteins 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
• 102100038126 Tenascin Human genes 0.000 description 1
• 108010008125 Tenascin Proteins 0.000 description 1
• 210000000068 Th17 cell Anatomy 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 102100026260 Titin Human genes 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 102000000887 Transcription factor STAT Human genes 0.000 description 1
• 108050007918 Transcription factor STAT Proteins 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108060008539 Transglutaminase Proteins 0.000 description 1
• 108010087472 Trehalase Proteins 0.000 description 1
• 102100029677 Trehalase Human genes 0.000 description 1
• 241000223259 Trichoderma Species 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 102000018594 Tumour necrosis factor Human genes 0.000 description 1
• 108050007852 Tumour necrosis factor Proteins 0.000 description 1
• 101710169479 Twitchin Proteins 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 235000009754 Vitis X bourquina Nutrition 0.000 description 1
• 235000012333 Vitis X labruscana Nutrition 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• 238000012452 Xenomouse strains Methods 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 201000010272 acanthosis nigricans Diseases 0.000 description 1
• 231100000230 acceptable toxicity Toxicity 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000018254 acute transverse myelitis Diseases 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 230000009824 affinity maturation Effects 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 239000000910 agglutinin Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
• 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000002547 anomalous effect Effects 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 230000009831 antigen interaction Effects 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 208000010928 autoimmune thyroid disease Diseases 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 230000004323 axial length Effects 0.000 description 1
• WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 1
• 229910052788 barium Inorganic materials 0.000 description 1
• DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• 235000013405 beer Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 238000007068 beta-elimination reaction Methods 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000006189 buccal tablet Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 238000000533 capillary isoelectric focusing Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
• 238000002983 circular dichroism Methods 0.000 description 1
• 238000007697 cis-trans-isomerization reaction Methods 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000005564 crystal structure determination Methods 0.000 description 1
• 239000008710 crystal-8 Substances 0.000 description 1
• 239000002178 crystalline material Substances 0.000 description 1
• 238000012866 crystallographic experiment Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000004925 denaturation Methods 0.000 description 1
• 230000036425 denaturation Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 229910000071 diazene Inorganic materials 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000012893 effector ligand Substances 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 210000002468 fat body Anatomy 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000003209 gene knockout Methods 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 150000002337 glycosamines Chemical group 0.000 description 1
• 239000003316 glycosidase inhibitor Substances 0.000 description 1
• 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
• 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 102000043557 human IFNG Human genes 0.000 description 1
• 102000057063 human MAPT Human genes 0.000 description 1
• 102000046949 human MSC Human genes 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 230000004727 humoral immunity Effects 0.000 description 1
• 150000001261 hydroxy acids Chemical group 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 108010085650 interferon gamma receptor Proteins 0.000 description 1
• 230000019734 interleukin-12 production Effects 0.000 description 1
• 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 210000004347 intestinal mucosa Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 150000002605 large molecules Chemical class 0.000 description 1
• 239000012633 leachable Substances 0.000 description 1
• 150000002611 lead compounds Chemical class 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 208000002741 leukoplakia Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 231100000053 low toxicity Toxicity 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 229960003151 mercaptamine Drugs 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229930003658 monoterpene Natural products 0.000 description 1
• 150000002773 monoterpene derivatives Chemical class 0.000 description 1
• 235000002577 monoterpenes Nutrition 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 108091005763 multidomain proteins Proteins 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 102000025599 myosin binding proteins Human genes 0.000 description 1
• 108091014719 myosin binding proteins Proteins 0.000 description 1
• 108010059725 myosin-binding protein C Proteins 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 150000004965 peroxy acids Chemical class 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 229940085991 phosphate ion Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 229940071643 prefilled syringe Drugs 0.000 description 1
• 206010036601 premature menopause Diseases 0.000 description 1
• 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000012846 protein folding Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
• 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000007430 reference method Methods 0.000 description 1
• 230000037425 regulation of transcription Effects 0.000 description 1
• 230000009712 regulation of translation Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 238000009774 resonance method Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 239000008299 semisolid dosage form Substances 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000000344 soap Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 238000001694 spray drying Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 239000013595 supernatant sample Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000036964 tight binding Effects 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000012451 transgenic animal system Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 102000003601 transglutaminase Human genes 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 238000009966 trimming Methods 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000007502 viral entry Effects 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 210000004885 white matter Anatomy 0.000 description 1
• 239000002023 wood Substances 0.000 description 1